We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As a result of the COVID-19 pandemic, the FDA has extended its enforcement discretion policy for six months for manufacturers of stem cell products to submit marketing applications to the FDA. Read More
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
Preliminary data from a German phase 1/2 trial showed that Pfizer’s and BioNTech’s mRNA-based coronavirus vaccine candidate is safe and generated immune responses in participants, the companies announced Monday. Read More
The British government announced Monday that it has reached COVID-19 vaccine supply deals with Pfizer/BioNTech and Valneva, locking in tens of millions of doses of their vaccine candidates for the country. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
RSS
